BioSpace News Archive

YS Biopharma Co., Ltd. (Nasdaq: YS) (“YS Biopharma” or the “Company”) today announced the results of its extraordinary general meeting (the “EGM”) held on February 22, 2024 in Hong Kong.

CTI Clinical Trials and Consulting, a full-service global research provider, is thrilled to announce that our North American laboratory facility has been granted the prestigious College of American Pathologists

The investigational medicinal product consisted of an autologous CD19 CAR T-cell therapy that was locally manufactured in the certified GMP laboratory of the Universitätsklinikum Erlangen in Erlangen, Germany.

AbCellera announced that executives from the Company will present at the following investor conferences.

Immunofoco announced a significant milestone, that following the approval by the CDE in China for the clinical trial application of IMC001, an EpCAM-targeting autologous CAR-T cell product for infusion, it also received the IND approval from the U.S. FDA, for the treatment of EpCAM-positive advanced gastrointestinal tumors, including but not limited to advanced gastric cancer and gastroesophageal junction adenocarcinoma.

OncoC4, Inc. (“OncoC4”) today announced that the first patient with metastatic castration resistant prostate cancer (“mCRPC”) has been dosed in a Phase 1/2 trial evaluating the anti-CTLA-4 antibody candidate BNT316/ONC-392 (gotistobart) in combination with radioligand therapy, lutetium (177Lu) vipivotide tetraxetan (Pluvicto®).

Nautilus Biotechnology, Inc. today announced the company will be participating in the TD Cowen 44th Annual Healthcare Conference.

Motus GI Holdings, Inc. today announced that it has entered into a definitive agreement for the immediate exercise of an outstanding Series B common stock purchase warrant held by an institutional investor to purchase an aggregate of 2,933,334 shares of the Company’s common stock.

Bionano Genomics, Inc., announced that optical genome mapping was included for the first time in the American College of Medical Genetics and Genomics technical laboratory standards documentation for solid tumor analysis.

IMUNON, Inc. (NASDAQ: IMNN) announces that an article titled “Strong immunogenicity & protection in mice with PlaCCine: A COVID-19 DNA vaccine formulated with a functional polymer” by Subeena Sood, Majed M. Matar, et. Al. [https://doi.org.10.1016/j.vaccine.2024.01.065] has been published in the peer-reviewed journal Vaccine, by Elsevier.